# reload+after+2024-01-22 17:27:06.295580
phone§(212) 593-4383
longBusinessSummary§Under normal market conditions, the fund will invest not less than 80% of its assets in component securities of the index. The index seeks to track the performance of the common stock of U.S. exchange-listed biotechnology companies with a primary product offering ("lead drug") that is typically in a Phase 1, Phase 2 or Phase 3 clinical trial stage of development, but prior to receiving marketing approval.
maxAge§86400
priceHint§2
yield§0.0034
totalAssets§11007053
navPrice§24.35474
currency§USD
category§Health
ytdReturn§-0.0047603
beta3Year§0.85
fundFamily§Virtus
fundInceptionDate§1418688000
legalType§Exchange Traded Fund
threeYearAverageReturn§-0.2092457
fiveYearAverageReturn§-0.0013378001
exchange§PCX
quoteType§ETF
shortName§Virtus LifeSci Biotech Clinical
longName§Virtus LifeSci Biotech Clinical Trials ETF
firstTradeDateEpochUtc§1418826600
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§a61d0066-1142-32d5-86ab-4e7fcf6d13c6
messageBoardId§finmb_274653436
gmtOffSetMilliseconds§-18000000
trailingPegRatio§None
